NEW YORK, May 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Kyle Sarwal and Ajit Johal to its Board of Directors.
Mr. Sarwal is a director and business development expert for SAJO Consulting, a company with management, research, scientific, and regulatory expertise. Mr. Sarwal has over 20 years’ experience in acquiring and growing companies, managing technology and information systems, managing teams and businesses, advisory and strategic planning.
Mr. Johal is a director and clinical subject matter expert for SAJO Consulting LLC. He is also the CEO of Next Level Medication Management INC, a Canadian based company dedicated to healthcare innovation and sustainability.
Mr. Johal is a graduate from the Leslie Dan Faculty of Pharmacy at the University of Toronto. He holds a Board Certification in Psychiatric Pharmacy, awarded by the Board of Pharmacy Specialties in the United States. He is a clinical instructor at UBC’s Faculty of Pharmaceutical Sciences and has worked as lead clinical pharmacist for a number of outreach programs including the Integrated Medication Management Program and the Coast Mental Health Medication Program.
“Ajit brings to Blake Insomnia Therapeutics a valued combination of pharmaceutical expertise with academic experience,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “His experience in psychiatric pharmacotherapy brings tremendous value to the development of Blake Insomnia’s portfolio of novel and innovative pharmaceutical products.” Both Mr. Sarwal and Mr. Ajit will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance.
Sajo Consulting LLC
Sajo designs solutions and strategies in getting products to market faster and smarter. Their research, scientific, regulatory and operational team puts best practice standards to work while building innovative solutions for constantly evolving industries.
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™.
Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact Birger Jan Olsen CEO Blake Insomnia Therapeutics Inc. 1 (888) 612-2905 news@blakeinsomnia.com
